Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00096-7/abstract?utm_campaign=update-langas&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_langas&_hsenc=p2ANqtz-9HVApjVMQhl-VwFHojSHE5Anz5J812XZx_GfjY7nyAwp3jbp9NWuYT0H9K1_iwKjQGvhcQvGKKtiWWjisM9LD8iNoK3Q&_hsmi=315988147&utm_content=315489009&utm_source=hs_email